About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID
Lyz2
lysozyme 2
MGI:96897
388 phenotypes from multigenic genotypes
Export: Excel File
Allelic Composition
Genetic Background
Annotated Term Reference
Abca1tm1Jp/Abca1tm1Jp
Abcg1tm1Tall/Abcg1tm1Tall
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6
abnormal bone marrow cell morphology/development J:190966
increased interleukin-17 secretion J:190966
increased interleukin-23 secretion J:190966
Adam17tm1Bbl/Adam17tm1Bbl
Lyz2tm1(cre)Ifo/0
involves: 129P2/OlaHsd
abnormal macrophage physiology J:139846
decreased circulating tumor necrosis factor level J:139846
decreased susceptibility to endotoxin shock J:139846
Adcy7tm1.1Pcst/Adcy7tm1.1Pcst
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6J
increased tumor necrosis factor secretion J:191067
peritoneal inflammation J:191067
Adora2btm1Msit/Adora2btm1Msit
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
decreased susceptibility to injury J:169155
Apba3tm1.1Ski/Apba3tm1.1Ski
Lyz2tm1(cre)Ifo/Lyz2+
B6.129-Apba3tm1.1Ski Lyz2tm1(cre)Ifo
decreased sensitivity to xenobiotic induced morbidity/mortality J:176742
decreased susceptibility to endotoxin shock J:176742
Apoetm1Bres/Apoetm1Bres
Bcl2tm1Irt/Bcl2tm1Irt
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
atherosclerotic lesions J:144243
normal cardiovascular system phenotype J:144243
normal homeostasis/metabolism phenotype J:144243
increased macrophage apoptosis J:144243
Apoetm1Lmh/Apoetm1Lmh
Ldlrtm1Her/Ldlrtm1Her
Lrp1tm2Her/Lrp1tm2Her
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S7/SvEvBrd
atherosclerotic lesions J:129557
increased susceptibility to atherosclerosis J:129557
Arg1tm1Pmu/Arg1tm1Pmu
Lyz2tm1(cre)Ifo/?
B6.Cg-Arg1tm1Pmu Lyz2tm1(cre)Ifo
decreased susceptibility to parasitic infection J:143229
Atf3tm1.1Hai/Atf3tm1.1Hai
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * FVB/N
decreased metastatic potential J:201626
Atg5tm1Myok/Atg5tm1Myok
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S/SvEv
abnormal circulating chemokine level J:235399
abnormal kidney morphology J:235399
abnormal macrophage physiology J:235399
abnormal renal glomerulus morphology J:235399
decreased body weight J:235399
decreased circulating interleukin-10 level J:235399
glomerulonephritis J:235399
increased anti-double stranded DNA antibody level J:235399
increased anti-nuclear antigen antibody level J:235399
increased autoantibody level J:235399
increased blood urea nitrogen level J:235399
increased circulating creatinine level J:235399
increased circulating interleukin-1 beta level J:235399
increased circulating interleukin-6 level J:235399
increased circulating interleukin-12b level J:235399
increased IgG level J:235399
increased lymphocyte cell number J:235399
increased monocyte cell number J:235399
increased neutrophil cell number J:235399
increased susceptibility to systemic lupus erythematosus J:235399
increased urine protein level J:235399
Atg7tm1Tchi/Atg7tm1Tchi
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6NCrlj * CBA/JNCrlj
abnormal circulating chemokine level J:235399
abnormal kidney morphology J:235399
abnormal macrophage physiology J:235399
abnormal renal glomerulus morphology J:235399
decreased body weight J:235399
decreased circulating interleukin-10 level J:235399
glomerulonephritis J:235399
increased anti-double stranded DNA antibody level J:235399
increased anti-nuclear antigen antibody level J:235399
increased autoantibody level J:235399
increased blood urea nitrogen level J:235399
increased circulating creatinine level J:235399
increased circulating interleukin-1 beta level J:235399
increased circulating interleukin-6 level J:235399
increased circulating interleukin-12b level J:235399
increased IgG level J:235399
increased lymphocyte cell number J:235399
increased monocyte cell number J:235399
increased neutrophil cell number J:235399
increased susceptibility to systemic lupus erythematosus J:235399
increased urine protein level J:235399
Atg7tm1Tchi/Atg7tm1Tchi
Lyz2tm1(cre)Ifo/Lyz2+
Tg(CAG-EGFP/Map1lc3b)53Nmz/0
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * DBA/2
abnormal circulating chemokine level J:235399
abnormal macrophage physiology J:235399
decreased circulating interleukin-10 level J:235399
increased circulating interleukin-1 beta level J:235399
increased circulating interleukin-6 level J:235399
Atg16l1tm2.1Mvlc/Atg16l1tm2.1Mvlc
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
impaired autophagy J:206931
Bcl2tm1Irt/Bcl2tm1Irt
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
increased macrophage apoptosis J:144243
Becn1tm1Ebr/Becn1tm1Ebr
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd
abnormal circulating chemokine level J:235399
abnormal kidney morphology J:235399
abnormal macrophage physiology J:235399
abnormal renal glomerulus morphology J:235399
abnormal spleen morphology J:235399
decreased body weight J:235399
decreased circulating interleukin-10 level J:235399
glomerulonephritis J:235399
increased anti-double stranded DNA antibody level J:235399
increased anti-nuclear antigen antibody level J:235399
increased autoantibody level J:235399
increased blood urea nitrogen level J:235399
increased circulating creatinine level J:235399
increased circulating interleukin-1 beta level J:235399
increased circulating interleukin-6 level J:235399
increased circulating interleukin-12b level J:235399
increased IgG level J:235399
increased lymphocyte cell number J:235399
increased monocyte cell number J:235399
increased neutrophil cell number J:235399
increased susceptibility to systemic lupus erythematosus J:235399
increased urine protein level J:235399
Casp8tm1Wll/Casp8tm1.1Yuan
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129S1/Sv * 129X1/SvJ * MF1
abnormal macrophage differentiation J:92722
Ccl2tm1.1Pame/Ccl2tm1.1Pame
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
normal immune system phenotype J:171379
Ccr2tm1Mpa/Ccr2tm1Mpa
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6 * CBA
abnormal wound healing J:189044
decreased macrophage cell number J:189044
Cd1d1tm1.1Aben/Cd1d1tm1.1Aben
Lyz2tm1(cre)Ifo/Lyz2+
B6.Cg-Cd1d1tm1.1Aben Lyz2tm1(cre)Ifo
decreased interferon-gamma secretion J:183087
decreased interleukin-4 secretion J:183087
normal immune system phenotype J:183087
Cd19tm1(cre)Cgn/Cd19+
Ptentm1Hwu/Ptentm1Hwu
Tg(IghelMD4)4Ccg/0
Tg(ML5sHEL)5Ccg/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
abnormal peripheral B cell anergy J:155314
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn
Tg(IghelMD4)4Ccg/0
Tg(ML5sHEL)5Ccg/0
involves: 129P2/OlaHsd * C57BL/6
decreased B cell number J:155314
normal immune system phenotype J:155314
Cdkn2btm1Wff/Cdkn2btm1Wff
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6
abnormal common myeloid progenitor cell morphology J:163498
abnormal megakaryocyte progenitor cell morphology J:163498
decreased erythroid progenitor cell number J:163498
increased monocyte cell number J:163498
myeloid hyperplasia J:163498
Cebpbtm1.1Elgaz/Cebpbtm1.1Elgaz
Lyz2em1.1Elgaz/Lyz2+
BALB/cJ-Cebpbtm1.1Elgaz Lyz2em1.1Elgaz
abnormal myeloid cell number J:247885
decreased circulating interleukin-10 level J:247885
decreased susceptibility to bacterial infection J:247885
decreased susceptibility to bacterial infection induced morbidity/mortality J:247885
decreased transforming growth factor level J:247885
increased circulating interleukin-6 level J:247885
increased circulating tumor necrosis factor level J:247885
Cers6tm1Arte/Cers6tm1Arte
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6N
normal homeostasis/metabolism phenotype J:215519
Cflartm1.1Pope/Cflartm1.2Pope
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd
abnormal abdominal lymph node morphology J:167430
abnormal B cell number J:167430
abnormal bone marrow cell number J:167430
abnormal CD4-positive, alpha beta T cell number J:167430
abnormal CD8-positive, alpha-beta T cell number J:167430
abnormal definitive hematopoiesis J:167430
abnormal erythropoiesis J:167430
abnormal lymphocyte cell number J:167430
abnormal myelopoiesis J:167430
abnormal spleen B cell follicle morphology J:167430
abnormal spleen marginal zone morphology J:167430
abnormal spleen morphology J:167430
abnormal spleen red pulp morphology J:167430
abnormal thymus corticomedullary boundary morphology J:167430
abnormal thymus morphology J:167430
anemia J:167430
decreased body size J:167430
decreased macrophage cell number J:167430
enlarged spleen J:167430
increased CD8-positive, alpha-beta T cell number J:167430
increased eosinophil cell number J:167430
increased granulocyte number J:167430
increased leukocyte cell number J:167430
increased monocyte cell number J:167430
increased neutrophil cell number J:167430
premature death J:167430
thrombocytosis J:167430
Cfptm2.1Song/Cfptm2.1Song
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129 * 129P2/OlaHsd * C57BL/6 * SJL
decreased susceptibility to induced arthritis J:165497
impaired complement alternative pathway J:165497
Chuktm1Lex/Chuktm1Lex
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S/SvEvBrd
impaired macrophage chemotaxis J:159873
impaired neutrophil chemotaxis J:159873
impaired neutrophil recruitment J:159873
Clec7atm1.1Bpip/Clec7atm1.1Bpip
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6J
abnormal macrophage physiology J:203908
decreased tumor necrosis factor secretion J:203908
impaired macrophage phagocytosis J:203908
increased susceptibility to fungal infection J:203908
Ctnnb1tm1Mmt/Ctnnb1+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129X1/SvJ
abnormal osteoclast differentiation J:178340
decreased bone marrow cell number J:178340
decreased bone resorption J:178340
increased bone volume J:178340
normal skeleton phenotype J:178340
Ctnnb1tm2Kem/Ctnnb1+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ
decreased trabecular bone volume J:178340
increased bone resorption J:178340
increased osteoclast cell number J:178340
osteoporosis J:178340
Ctnnb1tm2Kem/Ctnnb1tm2Kem
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ
decreased trabecular bone volume J:178340
increased bone resorption J:178340
increased osteoclast cell number J:178340
osteoporosis J:178340
Cxcr4tm2Yzo/Cxcr4tm2Yzo
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
normal adipose tissue phenotype J:217569
normal growth/size/body region phenotype J:217569
increased lymphocyte cell number J:217569
increased monocyte cell number J:217569
increased neutrophil cell number J:217569
Cybbtm1.1Abk/Cybbtm1.1Abk
Lyz2tm1(cre)Ifo/?
B6.Cg-Lyz2tm1(cre)Ifo Cybbtm1.1Abk
abnormal cued conditioning behavior J:245699
abnormal macrophage chemotaxis J:245699
decreased body length J:245699
decreased body weight J:245699
decreased cholesterol level J:245699
decreased circulating insulin level J:245699
decreased circulating LDL cholesterol level J:245699
decreased fasting circulating glucose level J:245699
decreased fat cell size J:245699
decreased susceptibility to diet-induced obesity J:245699
decreased triglyceride level J:245699
enlarged spleen J:245699
increased brain size J:245699
increased circulating HDL cholesterol level J:245699
increased epididymal fat pad weight J:245699
Elavl1tm1.1Bndr/Elavl1tm1.1Bndr
Lyz2tm1(cre)Ifo/Lyz2+
B6.129-Elavl1tm1.1Bndr
abnormal blood circulation J:182000
abnormal capillary morphology J:182000
abnormal physiological neovascularization J:182000
cellular necrosis J:182000
Elavl1tm1.1Dkon/Elavl1tm1.1Dkon
Lyz2tm1(cre)Ifo/Lyz2+
B6.129P2-Elavl1tm1.1Dkon Lyz2tm1(cre)Ifo
abnormal macrophage chemotaxis J:184388
normal immune system phenotype J:184388
increased circulating interleukin-1 beta level J:184388
increased circulating interleukin-6 level J:184388
increased circulating interleukin-12 level J:184388
increased circulating tumor necrosis factor level J:184388
increased colon adenocarcinoma incidence J:184388
increased colon adenoma incidence J:184388
increased incidence of tumors by chemical induction J:184388
increased macrophage cell number J:184388
increased monocyte cell number J:184388
increased sensitivity to xenobiotic induced morbidity/mortality J:184388
increased susceptibility to endotoxin shock J:184388
increased susceptibility to induced colitis J:184388
increased tumor growth/size J:184388
Elavl1tm1.1Dkon/Elavl1tm1.1Dkon
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6J
normal immune system phenotype J:184388
increased circulating interleukin-1 beta level J:184388
increased circulating interleukin-6 level J:184388
increased circulating interleukin-12 level J:184388
increased circulating tumor necrosis factor level J:184388
increased sensitivity to xenobiotic induced morbidity/mortality J:184388
increased susceptibility to endotoxin shock J:184388
Endoutm1Tft/Endoutm1Tft
Tg(IghelMD4)4Ccg/0
Tg(ML5sHEL)5Ccg/0
involves: 129S/SvEv * C57BL/6 * C57BL/6JSfd
decreased activation-induced B cell apoptosis J:208364
normal immune system phenotype J:208364
increased autoantibody level J:208364
Engtm2.1Hma/Engtm2.1Hma
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd
normal cardiovascular system phenotype J:212952
Esr1tm1.1Scma/Esr1tm1.1Scma
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6
abnormal osteoclast physiology J:156947
abnormal skeleton development J:156947
abnormal trabecular bone morphology J:156947
decreased compact bone mass J:156947
increased osteoclast cell number J:156947
Esr2tm1.1Pcn/Esr2tm1.1Pcn
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S2/SvPas
delayed wound healing J:165719
Fmnl1tm1.2Sdb/Fmnl1tm1.2Sdb
Lyz2tm1(cre)Ifo/Lyz2tm1(cre)Ifo
involves: C3H * C57BL/6 * FVB/N
abnormal Kupffer cell morphology J:250144
abnormal macrophage morphology J:250144
abnormal macrophage physiology J:250144
normal cardiovascular system phenotype J:250144
decreased macrophage cell number J:250144
normal growth/size/body region phenotype J:250144
normal hematopoietic system phenotype J:250144
impaired macrophage chemotaxis J:250144
normal mortality/aging J:250144
normal reproductive system phenotype J:250144
Fntbtm1.1Mbrg/Fntbtm1.2Mbrg
Krastm4Tyj/Kras+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S4/SvJae * BALB/cJ * C57BL/6 * FVB/N
decreased tumor growth/size J:158937
increased lung tumor incidence J:158937
increased lung weight J:158937
premature death J:158937
Fntbtm1.1Mbrg/Fntbtm1.2Mbrg
Krastm4Tyj/Kras+
Pggt1btm1Mbrg/Pggt1btm1.1Mbrg
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S4/SvJae * BALB/cJ * C57BL/6 * FVB/N
decreased tumor growth/size J:158937
increased lung tumor incidence J:158937
premature death J:158937
Fostm7Wag/Fostm7Wag
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
decreased interleukin-10 secretion J:175064
increased circulating interleukin-6 level J:175064
increased circulating interleukin-10 level J:175064
increased circulating tumor necrosis factor level J:175064
increased interleukin-6 secretion J:175064
increased susceptibility to endotoxin shock J:175064
increased tumor necrosis factor secretion J:175064
Fosl2tm2Wag/Fosl2tm2Wag
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
abnormal osteoclast differentiation J:137646
Fpr2tm1.1Jimw/Fpr2tm1.1Jimw
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129X1/SvJ
decreased susceptibility to induced colitis J:197568
Gbatm1Clk/Gbatm1.1Clk
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6J
abnormal enzyme/coenzyme activity J:117763
Gt(ROSA)26Sortm1(CAG-CAMK2G*T287D,-EGFP)Whua/Gt(ROSA)26Sor+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129 * C57BL/6
normal digestive/alimentary phenotype J:243363
Gt(ROSA)26Sortm1(OVAL/fla,GFP)Vnce/Gt(ROSA)26Sor+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6J
abnormal circulating cytokine level J:260047
abnormal renal glomerulus morphology J:260047
anemia J:260047
decreased B cell number J:260047
decreased body size J:260047
decreased body weight J:260047
decreased hematocrit J:260047
decreased lymphocyte cell number J:260047
enlarged lymph nodes J:260047
enlarged spleen J:260047
glomerulonephritis J:260047
increased inflammatory response J:260047
increased monocyte cell number J:260047
increased neutrophil cell number J:260047
increased T cell number J:260047
joint inflammation J:260047
joint swelling J:260047
small intestinal inflammation J:260047
Gt(ROSA)26Sortm1(OVAL/fla,GFP)Vnce/Gt(ROSA)26Sor+
Lyz2tm1(cre)Ifo/Lyz2+
Pycardtm1Vmd/Pycardtm1Vmd
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6J
normal growth/size/body region phenotype J:260047
normal immune system phenotype J:260047
increased circulating interferon-gamma level J:260047
increased circulating interleukin-6 level J:260047
increased circulating tumor necrosis factor level J:260047
Gt(ROSA)26Sortm1(OVAL/fla,GFP)Vnce/Gt(ROSA)26Sor+
Lyz2tm1(cre)Ifo/Lyz2+
Nlrc4tm1Vmd/Nlrc4tm1Vmd
involves: 129P2/OlaHsd * C57BL/6J * C57BL/6NCrl
normal immune system phenotype J:260047
normal skeleton phenotype J:260047
Hfetm1Wsr/Hfetm1Wsr
Lyz2tm1(cre)Ifo/?
involves: 129P2/OlaHsd * C57BL/6
normal homeostasis/metabolism phenotype J:132134
Hif1atm3Rsjo/Hif1atm3Rsjo
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ
abnormal leukocyte physiology J:117348
abnormal macrophage physiology J:107682
decreased inflammatory response J:107682
decreased susceptibility to induced arthritis J:107682
decreased tumor necrosis factor secretion J:107682
impaired macrophage chemotaxis J:107682
increased susceptibility to injury J:117348
Hif1atm3Rsjo/Hif1atm3Rsjo
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6
abnormal body temperature J:148597
abnormal systemic arterial blood pressure J:148597
decreased interleukin-1 alpha secretion J:148597
decreased interleukin-1 beta secretion J:148597
decreased interleukin-6 secretion J:148597
decreased interleukin-12 secretion J:148597
decreased sensitivity to xenobiotic induced morbidity/mortality J:148597
decreased susceptibility to endotoxin shock J:148597
decreased tumor necrosis factor secretion J:148597
Hmgb1tm1.1Ttg/Hmgb1tm1.1Ttg
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd
abnormal macrophage physiology J:205499
decreased macrophage cell number J:205499
normal hematopoietic system phenotype J:205499
impaired macrophage phagocytosis J:205499
increased circulating interleukin-1 beta level J:205499
increased circulating interleukin-18 level J:205499
increased interleukin-1 beta secretion J:205499
increased interleukin-18 secretion J:205499
increased macrophage apoptosis J:205499
increased sensitivity to induced cell death J:205499
increased susceptibility to bacterial infection J:205499
increased susceptibility to endotoxin shock J:205499
Hmox1tm1.1Gkl/Hmox1tm1.1Gkl
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129 * 129P2/OlaHsd * BALB/cJ * C57BL/6
decreased interferon-beta secretion J:148498
decreased susceptibility to bacterial infection induced morbidity/mortality J:148498
decreased susceptibility to viral infection J:148498
increased B cell number J:148498
increased CD4-positive, alpha beta T cell number J:148498
increased CD8-positive, alpha-beta T cell number J:148498
increased circulating tumor necrosis factor level J:148498
increased granulocyte number J:148498
increased interferon-gamma secretion J:148498
increased macrophage cell number J:148498
increased splenocyte proliferation J:148498
increased susceptibility to experimental autoimmune encephalomyelitis J:148498
Hmox1tm1.1Hes/Hmox1tm1.1Hes
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6J * C57BL/6N
abnormal cellular respiration J:214639
abnormal metabolism J:214639
abnormal mitochondrial physiology J:214639
abnormal redox activity J:214639
decreased circulating free fatty acid level J:214639
decreased fat cell size J:214639
decreased inflammatory response J:214639
decreased interleukin-1 beta secretion J:214639
decreased interleukin-6 secretion J:214639
decreased susceptibility to hepatic steatosis J:214639
decreased susceptibility to weight gain J:214639
decreased tumor necrosis factor secretion J:214639
improved glucose tolerance J:214639
increased energy expenditure J:214639
increased insulin sensitivity J:214639
Hsp90b1tm1Zhli/Hsp90b1tm1.1Zhli
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S/SvEv
abnormal cytokine secretion J:118427
abnormal inflammatory response J:118427
abnormal macrophage physiology J:118427
increased susceptibility to bacterial infection J:118427
premature death J:118427
Idh1tm1Mak/Idh1tm1Mak
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
abnormal blood homeostasis J:186700
abnormal bone marrow cell morphology/development J:186700
abnormal bone marrow cell physiology J:186700
abnormal myeloblast morphology/development J:186700
abnormal spleen morphology J:186700
anemia J:186700
decreased B cell number J:186700
decreased bone marrow cell number J:186700
decreased CD4-positive, alpha beta T cell number J:186700
decreased CD8-positive, alpha-beta T cell number J:186700
decreased common myeloid progenitor cell number J:186700
decreased hematocrit J:186700
decreased hemoglobin content J:186700
enlarged spleen J:186700
extramedullary hematopoiesis J:186700
normal hematopoietic system phenotype J:186700
increased CD4-positive, alpha beta T cell number J:186700
increased hematopoietic stem cell number J:186700
Idh1tm2Mak/Idh1tm2Mak
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
abnormal blood homeostasis J:186700
abnormal bone marrow cell morphology/development J:186700
abnormal bone marrow cell physiology J:186700
abnormal myeloblast morphology/development J:186700
abnormal spleen morphology J:186700
anemia J:186700
decreased B cell number J:186700
decreased bone marrow cell number J:186700
decreased CD4-positive, alpha beta T cell number J:186700
decreased CD8-positive, alpha-beta T cell number J:186700
decreased common myeloid progenitor cell number J:186700
decreased hematocrit J:186700
decreased hemoglobin content J:186700
enlarged spleen J:186700
extramedullary hematopoiesis J:186700
normal hematopoietic system phenotype J:186700
increased CD4-positive, alpha beta T cell number J:186700
increased hematopoietic stem cell number J:186700
Ifnb1tm2.1Lien/Ifnb1tm2.1Lien
Tyrc-2J/Tyrc-2J
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
decreased circulating interferon-alpha level J:172226
decreased circulating interferon-beta level J:172226
decreased susceptibility to bacterial infection J:172226
Ightm1Rbr/Igh+
Tg(IgkHyHEL10)1Rbr/0
Tg(ML5sHEL)5Ccg/0
involves: C57BL/6 * C57BL/6JSfd
abnormal B cell anergy J:132538
abnormal B cell morphology J:132538
decreased follicular B cell number J:132538
decreased marginal zone B cell number J:132538
increased immature B cell number J:132538
Ikbkbtm1Lex/Ikbkbtm1Lex
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S/SvEvBrd
impaired macrophage chemotaxis J:159873
impaired neutrophil chemotaxis J:159873
impaired neutrophil recruitment J:159873
Ikbkbtm2Mka/Ikbkbtm2Mka
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129/Sv * 129P2/OlaHsd
increased macrophage apoptosis J:80159
Il1r1tm1Quan/Il1r1tm1Quan
Lyz2tm1(cre)Ifo/Lyz2tm1(cre)Ifo
involves: 129P2/OlaHsd * C57BL/6
abnormal inflammatory response J:219864
abnormal microglial cell activation J:219864
Il1r1tm1Roml/Il1r1tm1Roml
Nlrp3tm1Hhf/Nlrp3+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129 * C57BL/6
normal mortality/aging J:150054
skin inflammation J:150054
Il1rntm1.1Cga/Il1rntm1.1Cga
Lyz2tm1(cre)Ifo/Lyz2+
D1.Cg-Il1rntm1.1Cga Lyz2tm1(cre)Ifo
abnormal chemokine secretion J:162760
increased interferon-gamma secretion J:162760
increased interleukin-1 beta secretion J:162760
increased interleukin-6 secretion J:162760
increased interleukin-17 secretion J:162760
increased susceptibility to induced arthritis J:162760
increased T cell proliferation J:162760
Il4ratm1Fbb/Il4ratm2Fbb
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * BALB/c
abnormal immune system physiology J:114751
abnormal intestinal goblet cell morphology J:114751
abnormal macrophage physiology J:114751
decreased susceptibility to parasitic infection J:114751
granulomatous inflammation J:114751
increased susceptibility to parasitic infection J:114751
liver fibrosis J:114751
liver inflammation J:114751
premature death J:114751
weight loss J:114751
Il4ratm2Fbb/Il4ratm2Fbb
Lyz2tm1(cre)Ifo/?
involves: 129P2/OlaHsd * BALB/c
decreased core body temperature J:178294
decreased fatty acid level J:178294
Il6ratm1.1Drew/Il6ratm1.1Drew
Lyz2tm1(cre)Ifo/Lyz2+
involves: C57BL/6 * C57BL/6N * SJL
normal immune system phenotype J:160966
Il6ratm1.1Jcbr/Il6ratm1.1Jcbr
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
decreased circulating interleukin-1 beta level J:188445
decreased circulating tumor necrosis factor level J:188445
decreased susceptibility to parasitic infection J:188445
Il10tm2Roer/Il10tm2Roer
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
abnormal cytokine secretion J:117122
abnormal inflammatory response J:117122
increased susceptibility to endotoxin shock J:117122
Il10ratm1.1Jack/Il10ratm1.1Jack
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * BALB/c * C57BL/6
abnormal chemokine level J:157787
abnormal cytokine level J:157787
increased circulating interferon-gamma level J:157787
increased circulating interleukin-1 alpha level J:157787
increased circulating interleukin-1 beta level J:157787
increased circulating interleukin-2 level J:157787
increased circulating interleukin-12 level J:157787
increased circulating interleukin-17 level J:157787
increased circulating tumor necrosis factor level J:157787
increased susceptibility to parasitic infection J:157787
Il12btm1Jm/Il12btm1Jm
Stat3tm2Aki/Stat3tm2Aki
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6
normal digestive/alimentary phenotype J:83280
Il15ratm1Ama/Il15ratm2.1Ama
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6J
abnormal immune system physiology J:155298
abnormal NK cell differentiation J:155298
abnormal NK cell physiology J:155298
decreased CD8-positive, alpha-beta T cell number J:155298
decreased memory T cell number J:155298
decreased NK cell number J:155298
Il15ratm1Ama/Il15ratm2.1Ama
Lyz2tm1(cre)Ifo/0
Tg(Itgax-cre)1-1Reiz/0
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA
abnormal immune system physiology J:155298
decreased CD8-positive, alpha-beta T cell number J:155298
decreased memory T cell number J:155298
decreased NK cell number J:155298
Inpp5dtm1Rav/Inpp5dtm1.1Rav
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
abnormal spleen marginal zone macrophage morphology J:119256
absent marginal zone B cells J:119256
enlarged spleen J:119256
Itgamtm1Myd/Itgamtm1Myd
Syktm1Tyb/Syktm1.2Tara
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJae * C57BL/6
impaired granulocyte bactericidal activity J:155479
Itgavtm2Hyn/Itgavtm2.1Hyn
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * FVB
colitis J:125508
impaired macrophage phagocytosis J:125508
increased autoantibody level J:125508
Itgb3tm1Hyn/Itgb3tm1.1Wlbcr
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
abnormal osteoclast differentiation J:224675
abnormal osteoclast morphology J:224675
altered tumor pathology J:224675
altered tumor susceptibility J:224675
decreased collagen level J:224675
decreased osteoclast cell number J:224675
increased bone mineral density J:224675
increased trabecular bone volume J:224675
osteopetrosis J:224675
Junbtm3Wag/Junbtm3Wag
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
abnormal bone ossification J:88126
abnormal osteoclast morphology J:88126
abnormal trabecular bone morphology J:88126
Klf2tm2Ling/Klf2tm2Ling
Lyz2tm1(cre)Ifo/0
involves: 129P2/OlaHsd * 129S6/SvEvTac
decreased Ly6C low monocyte number J:239509
Klf4tm1Khk/Klf4tm1Khk
Lyz2tm1(cre)Ifo/0
involves: 129P2/OlaHsd * 129S6/SvEvTac
decreased Ly6C low monocyte number J:239509
Kmt2atm1.1(Sh3gl1)Lcc/Kmt2a+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6
enlarged liver J:205605
enlarged lymph nodes J:205605
enlarged spleen J:205605
increased leukemia incidence J:205605
myeloid hyperplasia J:205605
premature death J:205605
Kmt2atm1.1Erns/Kmt2atm1.1Erns
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL
normal immune system phenotype J:147265
Krastm4Tyj/Kras+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S4/SvJae
increased lung tumor incidence J:158937
increased lung weight J:158937
postnatal lethality, complete penetrance J:158937
Krastm4Tyj/Kras+
Pggt1btm1Mbrg/Pggt1b+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129/Sv * 129P2/OlaHsd * C57BL/6
abnormal definitive hematopoiesis J:122107
abnormal liver morphology J:122107
abnormal spleen morphology J:122107
decreased lymphocyte cell number J:122107
increased lung adenocarcinoma incidence J:122107
increased lung adenoma incidence J:122107
increased lung tumor incidence J:122107
increased lung weight J:122107
increased neutrophil cell number J:122107
postnatal lethality, incomplete penetrance J:122107
respiratory distress J:122107
weight loss J:122107
Krastm4Tyj/Kras+
Pggt1btm1Mbrg/Pggt1btm1Mbrg
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129/Sv * 129P2/OlaHsd * C57BL/6
increased lung adenoma incidence J:122107
increased lung tumor incidence J:122107
increased lung weight J:122107
postnatal growth retardation J:122107
postnatal lethality, incomplete penetrance J:122107
Ldlrtm1Her/Ldlrtm1Her
Lrp1tm2Her/Lrp1tm2Her
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S7/SvEvBrd
impaired macrophage phagocytosis J:137404
Ldlrtm1Her/Ldlrtm1Her
Lrp1tm2Her/Lrp1tm2Her
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J
abnormal microglial cell physiology J:144185
altered response to CNS ischemic injury J:144185
decreased cerebral infarction size J:144185
decreased susceptibility to ischemic brain injury J:144185
Ltbrtm1.1Thhe/Ltbrtm1.1Thhe
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6 * SJL
abnormal macrophage physiology J:183109
Ltbrtm1Avt/Ltbrtm1Avt
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd
increased susceptibility to bacterial infection J:158663
Lyz2tm1(cre)Ifo/Lyz2+
Pdcd10tm1Wami/Pdcd10tm1Wami
involves: 129 * 129P2/OlaHsd * C57BL/6
abnormal neutrophil morphology J:256076
abnormal neutrophil physiology J:256076
increased circulating creatinine level J:256076
renal tubular necrosis J:256076
Lyz2tm1(cre)Ifo/Lyz2+
Nfkbiztm1.1Muta/Nfkbiztm1.1Muta
involves: 129P2/OlaHsd * C57BL/6
normal immune system phenotype J:194832
Lyz2tm1(cre)Ifo/Lyz2+
Pikfyvetm1b(EUCOMM)Hmgu/Pikfyvetm1b(EUCOMM)Hmgu
involves: 129P2/OlaHsd * C57BL/6N
abnormal alveolar macrophage morphology J:244776
abnormal alveolar macrophage physiology J:244776
decreased alveolar macrophage number J:244776
decreased regulatory T cell number J:244776
normal immune system phenotype J:244776
increased eosinophil cell number J:244776
increased interleukin-4 secretion J:244776
increased interleukin-13 secretion J:244776
increased susceptibility to type I hypersensitivity reaction J:244776
Lyz2tm1(cre)Ifo/Lyz2tm1(cre)Ifo
Nrrostm1Wouy/Nrrostm1Wouy
involves: 129P2/OlaHsd
abnormal cellular extravasation J:209569
increased susceptibility to experimental autoimmune encephalomyelitis J:209569
oxidative stress J:209569
Map3k7tm1.1Gkl/Map3k7tm1.1Gkl
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
decreased circulating interleukin-10 level J:211916
decreased interleukin-10 secretion J:211916
increased circulating interleukin-1 beta level J:211916
increased circulating tumor necrosis factor level J:211916
increased inflammatory response J:211916
increased interleukin-1 beta secretion J:211916
increased interleukin-6 secretion J:211916
increased interleukin-10 secretion J:211916
increased sensitivity to induced morbidity/mortality J:211916
increased susceptibility to endotoxin shock J:211916
increased tumor necrosis factor secretion J:211916
Map3k8tm1.1Gkl/Map3k8tm1.1Gkl
Lyz2tm1(cre)Ifo/Lyz2+
involves: C57BL/6 * FVB/N
normal homeostasis/metabolism phenotype J:193546
normal neoplasm J:193546
Mapk8tm1Rjd/Mapk8tm1Rjd
Mapk9tm2.1Rjd/Mapk9tm2.1Rjd
Lyz2tm1(cre)Ifo/Lyz2+
B6J.Cg-Lyz2tm1(cre)Ifo Mapk9tm2.1Rjd Mapk8tm1Rjd
abnormal chemokine level J:192551
abnormal circulating chemokine level J:192551
abnormal circulating cytokine level J:192551
abnormal gluconeogenesis J:192551
abnormal glucose homeostasis J:192551
abnormal glycogen homeostasis J:192551
abnormal lipid homeostasis J:192551
abnormal macrophage differentiation J:192551
abnormal macrophage physiology J:192551
decreased circulating glucose level J:192551
decreased circulating insulin level J:192551
decreased inflammatory response J:192551
decreased lean body mass J:192551
decreased macrophage cell number J:192551
decreased macrophage cytokine production J:192551
decreased pancreatic beta cell proliferation J:192551
normal homeostasis/metabolism phenotype J:192551
impaired macrophage chemotaxis J:192551
improved glucose tolerance J:192551
increased insulin secretion J:192551
increased insulin sensitivity J:192551
small pancreatic islets J:192551
Mcl1tm1Ywh/Mcl1tm1Ywh
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac * C57BL/6
abnormal neutrophil physiology J:137502
decreased granulocyte number J:137502
decreased neutrophil cell number J:137502
normal immune system phenotype J:137502
impaired neutrophil recruitment J:137502
increased eosinophil cell number J:137502
Mef2ctm1Jjs/Mef2ctm1Jjs
Mir223tm1Fcam/Mir223tm1Fcam
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129 * C57BL/6
abnormal neutrophil differentiation J:140009
abnormal neutrophil physiology J:140009
increased neutrophil cell number J:140009
Myd88tm1Aki/Myd88tm1Aki
Tg(IghelMD4)4Ccg/0
Tg(KLK4mHEL)6Ccg/0
involves: 129P2/OlaHsd * C57BL/6
decreased mature B cell number J:115059
increased B-1 B cell number J:115059
Myd88tm1Hlz/Myd88tm1Hlz
Lyz2tm1(cre)Ifo/Lyz2+
B6.129P2-Myd88tm1Hlz Lyz2tm1(cre)Ifo
abnormal chemokine level J:188968
normal immune system phenotype J:188968
increased circulating alanine transaminase level J:188968
increased circulating aspartate transaminase level J:188968
increased circulating tumor necrosis factor level J:188968
increased susceptibility to injury J:188968
Myo18atm1c(KOMP)Wtsi/Myo18atm1c(KOMP)Wtsi
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6N
normal immune system phenotype J:277320
n-TUtca2tm2Mym/n-TUtca2tm2.1Mym
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
increased apoptosis J:130723
increased cellular sensitivity to oxidative stress J:130723
premature death J:130723
Naipctm1Kmma/Naipctm1Kmma
Lyz2tm1(cre)Ifo/Lyz2+
B6.Cg-Lyz2tm1(cre)Ifo Naipctm1Kmma
decreased susceptibility to induced colitis J:222114
normal neoplasm J:222114
Nfat5tm1.1Itl/Nfat5tm1.1Itl
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6NTac * FVB/N
abnormal chloride level J:201429
abnormal lymphatic vessel morphology J:201429
increased mean systemic arterial blood pressure J:201429
Nfatc1tm3Glm/Nfatc1tm3Glm
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
normal skeleton phenotype J:144598
Nfe2l2tm1Mym/Nfe2l2tm1Mym
n-TUtca2tm2Mym/n-TUtca2tm2.1Mym
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
increased apoptosis J:130723
increased cellular sensitivity to hydrogen peroxide J:130723
increased cellular sensitivity to oxidative stress J:130723
Nfkbiatm1Kbp/Nfkbiatm1Kbp
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
normal hematopoietic system phenotype J:97945
Nlrp3tm1Flv/Nlrp3tm1Hhf
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129 * C57BL/6
increased inflammatory response J:150054
postnatal lethality, complete penetrance J:150054
Nlrp3tm1Hhf/Nlrp3+
Rag1tm1Mom/Rag1tm1Mom
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129/Sv * 129P2/OlaHsd * C57BL/6
absent B cells J:150054
absent T cells J:150054
postnatal lethality, complete penetrance J:150054
reddish skin J:150054
scaly skin J:150054
slow postnatal weight gain J:150054
Nlrp3tm1Hhf/Nlrp3+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129/Sv * 129P2/OlaHsd * C57BL/6
abnormal circulating chemokine level J:150054
abnormal circulating cytokine level J:150054
abnormal intestine morphology J:150054
abnormal kidney morphology J:150054
hairless J:150054
increased circulating interleukin-1 beta level J:150054
increased circulating interleukin-6 level J:150054
increased circulating interleukin-18 level J:150054
increased circulating tumor necrosis factor level J:150054
increased inflammatory response J:150054
increased leukocyte cell number J:150054
increased neutrophil cell number J:150054
postnatal lethality, complete penetrance J:150054
reddish skin J:150054
scaly skin J:150054
slow postnatal weight gain J:150054
thrombocytosis J:150054
Nlrp3tm1Hhf/Nlrp3+
Pycardtm1Flv/Pycardtm1Flv
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129 * C57BL/6
no abnormal phenotype detected J:150054
Nlrp3tm2Hhf/Nlrp3+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129/Sv * 129P2/OlaHsd * C57BL/6
perinatal lethality, complete penetrance J:150054
Notch2tm2.1Ecan/Notch2tm2.1Ecan
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6J
normal skeleton phenotype J:246017
Notch2tm2.1Ecan/Notch2tm2.1Ecan
Lyz2tm1(cre)Ifo/Lyz2tm1(cre)Ifo
involves: 129P2/OlaHsd * C57BL/6J
normal skeleton phenotype J:246017
Nr3c1tm2.1Ljm/Nr3c1tm2.1Ljm
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S6/SvEvTac
abnormal interleukin-6 secretion J:197150
abnormal monocyte cell number J:197150
altered response to CNS ischemic injury J:197150
decreased susceptibility to neuronal excitotoxicity J:197150
increased interleukin-1 beta secretion J:197150
Nr3c1tm2Gsc/Nr3c1tm2Gsc
Lyz2tm1(cre)Ifo/Lyz2+
B6.129P2-Lyz2tm1(cre)Ifo Nr3c1tm2Gsc
normal immune system phenotype J:137157
Nr3c1tm2Gsc/Nr3c1tm2Gsc
Lyz2tm1(cre)Ifo/Lyz2+
C.129P2-Lyz2tm1(cre)Ifo Nr3c1tm2Gsc
normal skeleton phenotype J:160669
P4hbtm1.1Geno/P4hbtm1.2Geno
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd
decreased neutrophil cell number J:197556
impaired neutrophil recruitment J:197556
Pcyt1atm1Irt/Pcyt1atm1Irt
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129 * C57BL/6J
abnormal immune cell physiology J:65639
abnormal macrophage physiology J:65639
Plekhf1tm1.1Caox/Plekhf1tm1.1Caox
Lyz2tm1(cre)Ifo/Lyz2+
B6.Cg-Plekhf1tm1.1Caox Lyz2tm1(cre)Ifo
abnormal cytokine secretion J:277440
abnormal endocytosis J:277440
abnormal macrophage physiology J:277440
decreased circulating interferon-beta level J:277440
decreased circulating interleukin-6 level J:277440
decreased circulating tumor necrosis factor level J:277440
increased susceptibility to bacterial infection J:277440
increased susceptibility to bacterial infection induced morbidity/mortality J:277440
Pmltm1(PML/RARA)Ley/Pml+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * BALB/cJ * C57BL/6
normal hematopoietic system phenotype J:172024
increased leukemia incidence J:172024
Ppargtm1.1Gonz/Ppargtm1.1Gonz
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6
abnormal kidney morphology J:168799
abnormal macrophage activation involved in immune response J:168799
abnormal nephron morphology J:168799
abnormal peritoneal macrophage morphology J:168799
abnormal podocyte foot process morphology J:168799
abnormal renal glomerulus morphology J:168799
albuminuria J:168799
enlarged kidney J:168799
expanded mesangial matrix J:168799
fused podocyte foot processes J:168799
glomerulonephritis J:168799
impaired macrophage phagocytosis J:168799
increased anti-double stranded DNA antibody level J:168799
increased anti-nuclear antigen antibody level J:168799
increased anti-single stranded DNA antibody level J:168799
increased autoantibody level J:168799
increased circulating creatine level J:168799
increased IgG level J:168799
increased IgM level J:168799
increased kidney weight J:168799
increased renal glomerulus apoptosis J:168799
increased renal glomerulus basement membrane thickness J:168799
increased urine protein level J:168799
mesangial cell hyperplasia J:168799
renal glomerulus hypertrophy J:168799
Prkcdtm1Qxu/Prkcdtm1Qxu
Tg(IghelMD4)4Ccg/0
Tg(KLK4mHEL)6Ccg/0
involves: 129P2/OlaHsd * C57BL/6
normal immune system phenotype J:76134
Prkcdtm1Qxu/Prkcdtm1Qxu
Tg(IghelMD4)4Ccg/0
Tg(ML5sHEL)5Ccg/0
involves: 129P2/OlaHsd * C57BL/6
abnormal B cell physiology J:76134
abnormal B cell proliferation J:76134
abnormal self tolerance J:76134
abnormal spleen primary B follicle morphology J:76134
autoimmune response J:76134
decreased B cell number J:76134
normal immune system phenotype J:76134
increased spleen germinal center number J:76134
Ptentm1Hwu/Ptentm1Hwu
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S4/SvJae
abnormal alveolar macrophage morphology J:148947
abnormal cytokine level J:148947
abnormal macrophage chemotaxis J:148947
abnormal neutrophil physiology J:114699, J:145331, J:148947
decreased susceptibility to bacterial infection J:148947
decreased susceptibility to bacterial infection induced morbidity/mortality J:148947
impaired neutrophil recruitment J:148947
increased susceptibility to bacterial infection J:148947
increased susceptibility to bacterial infection induced morbidity/mortality J:148947
lung inflammation J:148947
pulmonary edema J:148947
Ptgestm1.1Gaf/Ptgestm1.1Gaf
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129 * C57BL/6
abnormal leukocyte physiology J:210141
abnormal vascular wound healing J:210141
decreased prostaglandin level J:210141
increased leukocyte cell number J:210141
increased prostaglandin level J:210141
Ptpmt1tm2.1Ckq/Ptpmt1tm2.1Ckq
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL
abnormal aerobic respiration J:194929
normal hematopoietic system phenotype J:194929
normal immune system phenotype J:194929
Ptpn11tm1Ckq/Ptpn11+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J
increased acute promyelocytic leukemia incidence J:177285
myeloid hyperplasia J:177285
premature death J:177285
Pycardtm1Ayaz/Pycardtm1Ayaz
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6J
decreased incidence of tumors by chemical induction J:191239
decreased interleukin-1 alpha secretion J:191239
decreased interleukin-1 beta secretion J:191239
decreased interleukin-6 secretion J:191239
decreased tumor necrosis factor secretion J:191239
Rac1tm1Djk/Rac1tm1.1Djk
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
decreased acute inflammation J:83457
decreased leukocyte cell number J:83457
decreased neutrophil cell number J:83457
impaired neutrophil chemotaxis J:83457
impaired neutrophil recruitment J:83457
Rb1cc1tm1.1Guan/Rb1cc1tm1.1Guan
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd
normal immune system phenotype J:235399
Rfx5tm1Ifo/Rfx5tm1.1Ifo
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129 * C57BL/6 * C.B-20
abnormal MHC II cell surface expression on macrophages J:67924
Rnf146tm1.1Rtpl/Rnf146tm1.1Rtpl
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6J
abnormal compact bone morphology J:243612
abnormal osteoclast differentiation J:243612
decreased bone mineral density J:243612
decreased bone trabecula number J:243612
decreased compact bone thickness J:243612
decreased trabecular bone mass J:243612
decreased trabecular bone volume J:243612
increased bone trabecular spacing J:243612
increased circulating tumor necrosis factor level J:243612
increased osteoclast cell number J:243612
normal skeleton phenotype J:243612
Rnf146tm1.1Rtpl/Rnf146tm1.1Rtpl
Sh3bp2tm1c(KOMP)Wtsi/Sh3bp2tm1c(KOMP)Wtsi
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6J * C57BL/6N
normal skeleton phenotype J:243612
Rpl13atm1.1Mazu/Rpl13atm1.1Mazu
Lyz2tm1(cre)Ifo/Lyz2+
involves: C57BL/6
abnormal cytokine level J:194920
abnormal lung morphology J:194920
abnormal macrophage chemotaxis J:194920
hypoactivity J:194920
increased blood urea nitrogen level J:194920
increased circulating aspartate transaminase level J:194920
increased circulating tumor necrosis factor level J:194920
premature death J:194920
tachypnea J:194920
Rxratm1Krc/Rxratm1Krc
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
abnormal kidney morphology J:168799
abnormal macrophage activation involved in immune response J:168799
abnormal nephron morphology J:168799
abnormal peritoneal macrophage morphology J:168799
abnormal podocyte foot process morphology J:168799
abnormal renal glomerulus morphology J:168799
albuminuria J:168799
enlarged kidney J:168799
expanded mesangial matrix J:168799
fused podocyte foot processes J:168799
glomerulonephritis J:168799
impaired macrophage phagocytosis J:168799
increased anti-double stranded DNA antibody level J:168799
increased anti-nuclear antigen antibody level J:168799
increased anti-single stranded DNA antibody level J:168799
increased autoantibody level J:168799
increased circulating creatine level J:168799
increased IgG level J:168799
increased IgM level J:168799
increased kidney weight J:168799
increased renal glomerulus apoptosis J:168799
increased renal glomerulus basement membrane thickness J:168799
increased urine protein level J:168799
mesangial cell hyperplasia J:168799
renal glomerulus hypertrophy J:168799
Slc3a2tm1.1Yait/Slc3a2tm1.1Yait
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6NCrSlc
abnormal macrophage antigen presentation J:188365
abnormal macrophage differentiation J:188365
abnormal macrophage morphology J:188365
abnormal macrophage physiology J:188365
impaired macrophage phagocytosis J:188365
Socs3tm1Ayos/Socs3tm1Ayos
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129 * C57BL/6
decreased susceptibility to endotoxin shock J:92040
Socs3tm1Wsa/Socs3tm2Wsa
Lyz2tm1(cre)Ifo/?
involves: 129P2/OlaHsd * C57BL/6
abnormal macrophage physiology J:83645
Sqstm1tm2.1Jmos/Sqstm1tm2.1Jmos
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd
normal cellular phenotype J:194291
normal growth/size/body region phenotype J:194291
normal homeostasis/metabolism phenotype J:194291
Stat1tm1Rds/Stat1tm1Rds
Stat3tm2Aki/Stat3tm2Aki
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129/Sv * 129P2/OlaHsd * C57BL/6
abnormal colon morphology J:83280
colitis J:83280
increased CD4-positive, alpha beta T cell number J:83280
increased interferon-gamma secretion J:83280
increased interleukin-6 secretion J:83280
increased tumor necrosis factor secretion J:83280
Stat3tm2Aki/Stat3tm2Aki
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
abnormal colon morphology J:83280
colitis J:83280
increased CD4-positive, alpha beta T cell number J:83280
increased dendritic cell number J:83280
increased interferon-gamma secretion J:83280
increased interleukin-12 secretion J:83280
increased macrophage cell number J:83280
Stat3tm2Aki/Stat3tm2Aki
Tlr4tm1Aki/Tlr4tm1Aki
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
colitis J:83280
decreased interferon-gamma secretion J:83280
decreased susceptibility to endotoxin shock J:83280
Stat3tm2Aki/Stat3tm2Aki
Tnftm1Sek/Tnftm1Sek
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6 * CBA
colitis J:83280
increased interferon-gamma secretion J:83280
increased interleukin-6 secretion J:83280
increased interleukin-12b secretion J:83280
Stk11tm1Keis/Stk11tm1Keis
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd
increased circulating interleukin-10 level J:191723
Syktm1.1Nns/Syktm1.1Nns
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd
normal homeostasis/metabolism phenotype J:181715
normal immune system phenotype J:181715
normal mortality/aging J:181715
Syktm1Tyb/Syktm1.2Tara
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
abnormal neutrophil physiology J:155479
impaired granulocyte bactericidal activity J:155479
Tab2tm2.1Aki/Tab2tm2.1Aki
Tab3tm1Aki/Tab3tm1Aki
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
normal immune system phenotype J:195289
Tfpitm1.1Rdsi/Tfpitm1.1Rdsi
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S4/SvJaeSor * 129S6/SvEvTac * BALB/cJ * C57BL/6
abnormal circulating protein level J:164530
Tg(IghelMD4)4Ccg/0
Tg(KLK4mHEL)6Ccg/0
C57BL/6-Tg(IghelMD4)4Ccg Tg(KLK4mHEL)6Ccg
decreased B cell number J:89156
Tg(IghelMD4)4Ccg/?
Tg(KLK4mHEL)6Ccg/?
involves: C57BL/6
arrested B cell differentiation J:78307
decreased mature B cell number J:78307
increased immature B cell number J:78307
Tg(IghelMD4)4Ccg/0
Tg(KLK4mHEL)6Ccg/0
NOD.B6-Tg(IghelMD4)4Ccg Tg(KLK4mHEL)6Ccg/Dvs
decreased B cell number J:89156
Tg(IghelMD4)4Ccg/0
Tg(ML5sHEL)5Ccg/0
C57BL/6-Tg(IghelMD4)4Ccg Tg(ML5sHEL)5Ccg
abnormal B cell anergy J:78308, J:89156
abnormal central B cell anergy J:109923
abnormal germinal center B cell morphology J:109923
abnormal immature B cell morphology J:109923
abnormal mature B cell morphology J:109923
abnormal plasma cell morphology J:109923
abnormal pro-B cell morphology J:109923
abnormal spleen B cell follicle morphology J:109923
decreased B cell number J:89156
decreased IgM level J:78308, J:89156
Tg(IghelMD4)4Ccg/0
Tg(ML5sHEL)5Ccg/0
involves: C57BL/6
abnormal B cell anergy J:73608, J:132538
abnormal B cell physiology J:76134
abnormal spleen primary B follicle morphology J:76134
decreased B cell number J:76134
decreased marginal zone B cell number J:132538
Tg(IghelMD4)4Ccg/0
Tg(ML5sHEL)5Ccg/0
NOD.B6-Tg(IghelMD4)4Ccg Tg(ML5sHEL)5Ccg/Dvs
abnormal B cell anergy J:89156
abnormal B cell clonal deletion J:89156
abnormal B cell morphology J:89156
decreased IgM level J:89156
Tg(KLK4mHEL)6Ccg/?
involves: C57BL/6
no abnormal phenotype detected J:78307
Tg(KLK4mHEL)6Ccg/0
Tg(TcrHEL3A9)1Mmd/0
involves: C57BL/6 * C57BL/10 * C57BR/cd
decreased CD4-positive, alpha beta T cell number J:78309
decreased double-positive T cell number J:78309
Tg(ML5sHEL)5Ccg/0
C57BL/6-Tg(ML5sHEL)5Ccg
abnormal B cell anergy J:78308
abnormal circulating protein level J:78308
Tg(ML5sHEL)5Ccg/0
involves: C57BL/6JSfd * CBA
abnormal B cell anergy J:78308
abnormal T cell anergy J:78308
Tg(ML5sHEL)5Ccg/0
Tg(TcrHEL3A9)1Mmd/0
involves: C57BL/6 * C57BL/10 * C57BR/cd
abnormal CD4-positive, alpha beta T cell morphology J:78309
abnormal CD4-positive, alpha-beta T cell physiology J:78309
abnormal T cell activation J:78309
abnormal T cell proliferation J:78309
decreased CD4-positive, alpha beta T cell number J:78309
decreased double-positive T cell number J:78309
Tg(ML5sHEL)5Ccg/0
Tg(TcrHEL3A9)1Mmd/0
Tg(TLK2mHEL)2Ccg/0
involves: C57BL/6JSfd * C57BL/10 * C57BR/cd
abnormal CD4-positive, alpha beta T cell morphology J:78309
abnormal CD4-positive, alpha-beta T cell physiology J:78309
abnormal T cell activation J:78309
abnormal T cell proliferation J:78309
decreased CD4-positive, alpha beta T cell number J:78309
decreased double-positive T cell number J:78309
thyroid gland inflammation J:78309
Thbdtm1.1Hlwu/Thbdtm1.1Hlwu
Lyz2tm1(cre)Ifo/Lyz2+
B6.129-Thbdtm1.1Hlwu Lyz2tm1(cre)Ifo
decreased circulating interleukin-6 level J:188879
decreased circulating tumor necrosis factor level J:188879
decreased sensitivity to induced morbidity/mortality J:188879
decreased susceptibility to bacterial infection J:188879
decreased susceptibility to bacterial infection induced morbidity/mortality J:188879
decreased susceptibility to injury J:188879
decreased tumor necrosis factor secretion J:188879
Tlr4Lps-d/Tlr4Lps-d
Tg(IghelMD4)4Ccg/0
Tg(KLK4mHEL)6Ccg/0
involves: 129P2/OlaHsd * C3H/HeJ * C57BL/6
decreased B cell number J:115059
increased B-1 B cell number J:115059
Tlr9tm1Aki/Tlr9tm1Aki
Tg(IghelMD4)4Ccg/0
Tg(KLK4mHEL)6Ccg/0
involves: 129P2/OlaHsd * C57BL/6
decreased mature B cell number J:115059
increased B-1 B cell number J:115059
Tnftm1.1Sned/Tnftm1.1Sned
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129 * 129P2/OlaHsd * C57BL/6
abnormal chemokine secretion J:95684
decreased circulating tumor necrosis factor level J:95684
decreased susceptibility to autoimmune disorder J:95684
decreased susceptibility to endotoxin shock J:95684
hepatic necrosis J:95684
increased sensitivity to induced morbidity/mortality J:95684
increased susceptibility to bacterial infection J:95684
Tnftm2.1Gkl/Tnf+
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S/SvEv * 129S6/SvEvTac * C57BL/6J
weight loss J:108572
Tnftm2.1Gkl/Tnftm2.1Gkl
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J
weight loss J:108572
Traf6tm1.1Mpa/Traf6tm1.1Mpa
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
decreased circulating interleukin-6 level J:145306
decreased susceptibility to injury J:145306
Trim58tm2313.1Arte/Trim58tm2313.1Arte
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6N
increased susceptibility to induced colitis J:279270
Ube2ntm1Aki/Ube2ntm1Aki
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
abnormal macrophage physiology J:112287
Upf2tm1Btp/Upf2tm1Btp
Lyz2tm1(cre)Ifo/?
involves: 129P2/OlaHsd * C57BL/6 * CBA
normal immune system phenotype J:134765
Vegfatm2Gne/Vegfatm2Gne
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129/Sv * 129P2/OlaHsd
decreased inflammatory response J:107682
Vegfatm2Gne/Vegfatm2Gne
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129/Sv * 129P2/OlaHsd * C57BL/6
normal immune system phenotype J:148597
normal mortality/aging J:148597
Vegfatm2Gne/Vegfatm2Gne
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129/Sv * 129P2/OlaHsd * FVB/N
abnormal wound healing J:189044
Vegfatm2Gne/Vegfatm2Gne
Lyz2tm1(cre)Ifo/Lyz2+
Tg(KRT14-cre)1Cgn/0
involves: 129 * C57BL/6 * CBA * FVB/N
abnormal wound healing J:189044
Vhltm1Jae/Vhltm1Jae
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S4/SvJae
increased inflammatory response J:107682
Zc3h12ctm2c(EUCOMM)Hmgu/Zc3h12ctm2c(EUCOMM)Hmgu
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N
enlarged lymph nodes J:277714
increased B cell number J:277714
increased CD4-positive, alpha beta T cell number J:277714
increased effector memory CD8-positive, alpha-beta T cell number J:277714
increased immature B cell number J:277714
increased marginal zone B cell number J:277714
Zfp36tm1.1Xen/Zfp36tm1.1Xen
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N
abnormal myocardium layer morphology J:188677
abnormal pilomotor reflex J:188677
abnormal renal glomerulus morphology J:188677
abnormal small intestine morphology J:188677
alveolitis J:188677
arthritis J:188677
decreased body temperature J:188677
decreased body weight J:188677
enlarged lymph nodes J:188677
enlarged spleen J:188677
focal hepatic necrosis J:188677
increased blood urea nitrogen level J:188677
increased circulating alanine transaminase level J:188677
increased circulating tumor necrosis factor level J:188677
increased inflammatory response J:188677
increased lactate dehydrogenase level J:188677
increased spleen weight J:188677
increased susceptibility to endotoxin shock J:188677
lethargy J:188677
normal mortality/aging J:188677
tachypnea J:188677

Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
02/04/2020
MGI 6.14
The Jackson Laboratory